About bosu tinib
BCR-ABL tyrosine kinase inhibitor
Used for
- Treats chronic myeloid leukemia with the Philadelphia chromosome in adults.
- Used for newly diagnosed or previously treated disease, depending on treatment history.
Usual adult dose
Usually 400 mg once daily with food when newly diagnosed; 500 mg once daily after prior treatment. Dose may be adjusted.
Common side effects
- Diarrhea, nausea, vomiting, or abdominal pain
- Low blood cell counts
- Liver enzyme changes
- Rash, fatigue, or infection
Important warnings
- Can cause severe diarrhea, liver injury, and low blood cell counts.
- May cause fluid retention, kidney problems, or heart rhythm changes.
- Regular blood tests and monitoring are required.
- Swallow tablets whole with food; do not crush or split.
Pregnancy
May harm an unborn baby. Avoid pregnancy during treatment and use effective contraception.
Breastfeeding
Breastfeeding is not recommended during treatment and for at least two weeks after the last dose.
Interactions
- Avoid grapefruit and grapefruit juice.
- Strong CYP3A inhibitors or inducers can change bosutinib levels.
- Acid-reducing medicines can lower absorption; separate antacids or H2 blockers by two hours.
- Warfarin and other medicines affecting bleeding may require monitoring.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.